New Ether Treasury Firm ‘ETHZilla’ Emerges With $425M Funding and a DeFi Twist
Nasdaq-listed biotech company 180 Life Sciences (ATNF) is undergoing a significant transformation, rebranding as ETHZilla and pivoting to an ether-focused treasury strategy. This strategic shift is fueled by a substantial $425 million private investment in public equity (PIPE) financing round, slated to close by August 1st. The investment, secured from a diverse group of sixty institutional and crypto-native investors, including prominent names like Polychain Capital, Electric Capital, and GSR, alongside founders of leading Ethereum platforms such as Lido, Frax, and EigenLayer, signifies a major commitment to the company’s new direction.
The core of ETHZilla’s strategy involves accumulating ether (ETH) as its primary treasury asset. This approach aims to generate superior returns compared to traditional investment strategies. Electric Capital will act as the external asset manager, overseeing the strategic deployment of these ETH holdings. The company will employ a sophisticated on-chain yield generation program, leveraging a combination of staking, lending, and liquidity provision to maximize returns.
Complementing this financial strategy, ETHZilla will establish a “DeFi Council,” composed of Etherealize and other key players in the decentralized finance (DeFi) space. This council will provide valuable insights and guidance, contributing to the optimization of ETH treasury monetization. McAndrew Rudisill, the prospective chairman following the deal’s closure, highlighted the strategic vision: “Our strategy aims to provide investors with access to a high-yield potential ecosystem within the stablecoin and tokenized asset markets.” He further emphasized the assembling of a robust team blending expertise from traditional finance and DeFi to navigate this new phase.
ETHZilla’s move joins a growing trend of publicly traded companies embracing ETH as a core treasury asset. According to data from StrategicEtherReserve, publicly traded companies and DeFi treasuries collectively hold approximately $9.5 billion worth of ETH, representing around 2% of its total circulating supply. Despite the announcement, 180 Life Sciences’ shares experienced a 7% drop in early trading, settling at $2.69. This rebranding and strategic shift represent a bold gamble on the future of Ethereum and its potential for significant financial returns.
